Physician profile
John Kellum
NPI 1629042106
$200,088.59
in general payments reported to CMS, 2019-2025
21 companies · $9,470 in 2025
The $9,470 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $20K · 2021: $75K · 2022: $43K · 2023: $4,370 · 2024: $12K · 2025: $9,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Food and Beverage: $529 · Travel and Lodging: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,020.00 |
| Food and Beverage | $528.60 |
| Travel and Lodging | $501.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astute Medical, INC. | $66,022.57 | 2021-2022 | |
| Biomerieux INC | $33,700.15 | 2019-2024 | |
| Baxter Healthcare | $20,655.82 | 2019-2022 | |
| Astellas Pharma INC | $18,487.50 | 2021-2022 | |
| Chugai Pharmaceutical Co., Ltd. | $13,359.93 | 2019-2025 | |
| Nxstage Medical, INC. | $13,044.69 | 2019-2021 | |
| Astrazeneca Uk Limited | $7,000.00 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $6,860.00 | 2020-2021 | |
| Csl Behring | $4,230.00 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $4,000.00 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $3,360.00 | 2021 | |
| Tanabe Pharma America, INC. | $3,150.00 | 2023 | |
| Ge Healthcare | $1,750.00 | 2021 | |
| Cochlear Ltd | $1,650.00 | 2019 | |
| Janssen Research & Development, LLC | $1,500.00 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $470.00 | 2020 | |
| Becton, Dickinson and Company | $350.00 | 2025 | Hemosphere |
| Vantive US Healthcare LLC | $190.02 | 2025 | Renal - Acute |
| La Jolla Pharmaceutical Company | $167.73 | 2019 | |
| Shionogi INC | $120.18 | 2025 | Fetroja |
| Roche Diagnostics Corporation | $20.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kellum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.